目前对儿科差异化甲状腺癌的治疗方法
Pinar Ozgen Kiratli1, Bilge Volkan-Salanci2
1Department of Nuclear Medicine, Hacettepe University Medical Center, Ankara, Türkiye.
概括
儿童的分化甲状腺癌 (DTC) 是罕见的,与成人病例不同. 多学科的方法改善了儿科DTC患者的治疗结果和生活质量.
科学领域:
- 儿科瘤学 儿科瘤学
- 内分泌学 在内分泌学.
- 癌症研究 癌症研究
背景情况:
- 儿童群体中差异化甲状腺癌 (DTC) 呈现出与成人不同独特的临床和生物特征.
- 目前的管理指南主要是从成人数据中推断出来的,对儿童和青少年的具体研究有限.
- 关于儿科DTC的最佳患者管理和治疗策略,仍存在未解决的问题.
研究的目的:
- 审查关于儿童患者差异化甲状腺癌管理的现有文献.
- 为儿童DTC提供当前方法的概述.
- 突出需要在DTC治疗中考虑特定年龄的需要.
主要方法:
- 对专注于儿科差异化甲状腺癌的研究进行文献综述.
- 对儿童和青少年临床表现,生物行为和治疗结果的分析.
- 综合来自小队列和异质回顾性研究的数据.
主要成果:
- 儿科DTC虽然有侵略性,但表现出优异的整体生存率.
- 标准治疗包括甲状腺切除术,淋巴结剖析转移,以及潜在的-131放射治疗.
- 疾病的特征和管理在不同儿科年龄组之间有很大差异.
结论:
- 一个全面的,多学科的方法对于管理儿科DTC至关重要.
- 这种综合策略可以减少治疗副作用.
- 通过多学科团队优化护理,提高了年轻DTC患者的生活质量.
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K